Please login
Calendar of Events

Diagnostic and Therapeutic Strategies for the Management of Acquired Hemophilia A

 

Key Dates:

Meeting: Saturday, January 14, 2017 to Monday, January 16, 2017

 

Location:

Prerecorded

Online

 

Description:

Diagnostic and Therapeutic Strategies for the Management of Acquired Hemophilia A


The rarity of acquired hemophilia A (AHA) has resulted in a lack of awareness among clinicians, and this potentially life-threatening bleeding diathesis may go unrecognized. Although the two-fold objectives of treating AHA are clear—to control bleeding and remove the inhibitor—management is complex and often challenging. Diagnosis may be delayed, and AHA may be mistaken for congenital or other acquired bleeding disorders. The etiology of AHA is frequently unexplained and the bleeding presentation can be highly variable. Nevertheless, prompt recognition and management are crucial because mortality rates may be as high as 22%, especially early in the disease. Recent reviews of the management of AHA have recognized clinical practice gaps and the need for education in the timely recognition and evidence-based therapy of AHA. In this activity, expert faculty will discuss the differential diagnosis, laboratory findings, appropriate treatment, inhibitor eradication, safety concerns, and the need for long-term monitoring in AHA.
 
 

 

Diagnosis and Drug Monitoring in Bleeding Disorders: 2016 and Beyond

 

Key Dates:

Meeting: Saturday, January 14, 2017 to Monday, January 16, 2017

 

Location:

Prerecorded

Online

 

Description:

Educational opportunity from Rajiv K. Pruthi, MBBS, Maureane R. Hoffman, MD, PhD, and James Munn, BS, BSN, MS


Educational Objectives

After participating in this activity, participants should be better able to:

Review recent advances in the scientific understanding of hemostasis and the mechanisms by which hemostatic therapies work to counteract bleeding disorders

Summarize factors that can negatively affect the accuracy of hemostatic assays for the diagnosis and monitoring of bleeding disorders

Outline the benefits and limitations of investigational methods of assessing hemostasis, including global hemostatic assays and chromogenic assays

Describe how novel factor replacement therapies may impact standard practice for hemostatic monitoring

 

Program Overview

The challenges in diagnosing and monitoring bleeding disorders lie in the sensitivity of the tests, the complicated algorithms for investigating and interpreting results, the potential for assay discrepancy and inaccuracy, and intra- and inter-laboratory variability. Predicting and monitoring patient response to factor replacement products is equally challenging, and traditional diagnostic assays do not always provide adequate information regarding the hemostatic activity of these agents. All of these issues increase the risk of misdiagnosis or suboptimal management.

 

Laboratory Diagnosis and Therapeutic Monitoring in Hemophilia: Problems, Pitfalls, and Testing Pearls

 

Key Dates:

Meeting: Thursday, January 19, 2017 to Thursday, January 19, 2017

 

Location:

Blood CME center

www.bloodcmecenter.org

 

Description:

Date: Thursday, January 19, 2017, 1:00PM–2:00PM EST 



Target Audience 

This activity has been designed to meet the educational needs of pathologists, pathology residents, laboratory directors, laboratory managers and administrators, chief medical technologists, hospital administrators, registered nurses, support staff, and other clinicians who are interested in the management of patients with hemophilia A or hemophilia B. 



Educational Objectives 

After completing this activity, the participant should be better able to:

  • Review current issues, challenges, and problems related to the laboratory assessment of hemophilia A and B 

  • Discuss solutions – such as need to test both chromogenic and clot based assay to correctly diagnose non- severe hemophilia A and the need to accurately measure factor activity levels

  • Provide an overview of the recombinant FVIII and FIX replacement products (currently in late-stage development or recently approved)

  • Review some of the challenges facing clinical laboratories when monitoring some of these recombinant replacement products utilizing existing factor assays used in clinical laboratories.

  • Discuss advantages and disadvantages of proposed solutions as well as existing current recommendations (i.e. MASAC)






Chairperson:

Dorothy M. Adcock M.D.
 

Medical Director 

Colorado Coagulation, Laboratory Corporation of America® Holdings 



Presenting Faculty: 

Rajiv K Pruthi, M.B.B.S. 

Associate Professor, Mayo Clinic College of Medicine 

Co-Director, Special Coagulation Laboratory 

Director Comprehensive Hemophilia Center, Mayo Clinic 



Stefan Tiefenbacher, PhD 

Vice President, Laboratory Corporation of America® Holdings 

Technical Director of Coagulation 

Colorado Coagulation, A LabCorp Specialty Testing Group 



Program Agenda 



1:00 pm - 1:10pm ET



Introduction & Overview



1:10 pm — 1:25pm ET



What are and how do we solve the challenges and issues associated with the laboratory diagnosis of hemophilia A and B? 



1:25 pm — 1:40pm ET



What are and how do we solve the problems and overcome the pitfalls associated with monitoring factor replacement therapy?



1:40 pm — 1:55pm ET



Case Review and Discussion



1:55 pm — 2:00pm ET



Questions and Answers






 

HTRS 2017 Scientific Symposium

 

Key Dates:

Meeting: Thursday, April 06, 2017 to Saturday, April 08, 2017

 

Location:

Scottsdale

Arizona

 

Description:

Registration is now open for the HTRS 2017 Scientific Symposium April 6-8, 2017 in Scottsdale, AZ. The abstract submission deadline is January 6, 2017.  Six travel awards are available for young investigators and one travel award is available for a nurse.  Read more at www.htrs2017.com

 

XXXth International Symposium on Technical Innovations in Laboratory Hematology

ISLH

 

Key Dates:

Meeting: Thursday, May 04, 2017 to Saturday, May 06, 2017

 

Location:

Hawaii Convention Center

1801 Kalakaua Avenue. Honolulu, HI 96815

 

Description:

On behalf of the International Society for Laboratory Hematology (ISLH) and the North American Specialized Coagulation Laboratory Association (NASCOLA), we cordially invite you to attend ISLH 2017, the XXXth International Symposium on Technological Innovations in Laboratory Hematology. Please join your laboratory hematology colleagues in Honolulu, Hawaii from May 4-6, 2017.

CONFERENCE REGISTRATION

Opens: November 10, 2016

Early Deadline: April 4, 2017



ABSTRACT SUBMISSION

Opens: November 10, 2016

Deadline: February 1, 2017



TRAVEL AWARD APPLICATION

Early Deadline: December 10, 2016

Deadline: February 1, 2017

For more information see the website: https://www.islh.org/2017/program.php

 

ISTH 2017 Congress

International Society on Thrombosis and Haemostasis (ISTH)

 

Key Dates:

Meeting: Saturday, July 08, 2017 to Thursday, July 13, 2017

 

Location:

The CityCube Berlin and Messe Berlin Exhibition Gr

Berlin, Germany

 

Description:

At the ISTH 2017 Congress, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.



Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement. 



​For more information, visit the ISTH website at  http://www.isth2017.org/about.html